tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Fibroadenoma D018226 2 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Glucose Intolerance D018149 13 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Hypophosphatemia D017674 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Mucinoses D017520 2 associated lipids
Pityriasis Lichenoides D017514 2 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Porokeratosis D017499 1 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Hyperpigmentation D017495 11 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Polymyositis D017285 1 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Liver Failure, Acute D017114 11 associated lipids
IgG Deficiency D017099 1 associated lipids
IgA Deficiency D017098 2 associated lipids
Liver Failure D017093 5 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Critical Illness D016638 13 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Foot Ulcer D016523 4 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Fungemia D016469 2 associated lipids
Sweet Syndrome D016463 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Frei U and Wagner K Renal function in liver transplant patients receiving FK506 or cyclosporin A immunosuppressive therapy. 1994 Transplant. Proc. pmid:7527963
Morris R Modes of action of FK506, cyclosporin A, and rapamycin. 1994 Transplant. Proc. pmid:7527964
Celli S et al. Long-term survival of heart and liver xenografts with splenectomy and FK 506. 1993 Transplant. Proc. pmid:7679830
Beysens AJ et al. FK 506: monitoring in plasma or in whole blood? 1991 Transplant. Proc. pmid:1721263
Hashikura Y et al. Immunosuppressant switching between cyclosporine and tacrolimus after liver transplantation. 1996 Transplant. Proc. pmid:8623218
Grewal HP et al. Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. 1998 Transplant. Proc. pmid:9636558
Tanabe K et al. Malabsorption of tacrolimus in kidney transplant recipients: a Japanese single center experience. 2000 Transplant. Proc. pmid:11119906
Yao B et al. The incidence of posttransplantation diabetes mellitus during follow-up in kidney transplant recipients and relationship to Fok1 vitamin D receptor polymorphism. 2013 Jan-Feb Transplant. Proc. pmid:23375298
Vilalta R et al. Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation. 2003 Transplant. Proc. pmid:12644102
Rath T and Küpper M Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715967
Morell Ginestà M et al. Histology and immunopathology of heart and liver xenografts under low-dose tacrolimus. 2002 Transplant. Proc. pmid:11959305
Mazzaferro V et al. Studies of the hepatotrophic qualities of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689913
Sigal NH et al. Is FKBP involved in the immunosuppressive and/or toxic mechanism of action of FK 506? 1991 Transplant. Proc. pmid:1721295
Troppmann C et al. Perioperative immunosuppression as a critical determinant of early outcome after discordant xenoislet transplantation: a comparative study. 1996 Transplant. Proc. pmid:8623487
Braun F et al. Primary tacrolimus immunosuppression in kidney recipients considered "higher immunologic risk". 2000 Transplant. Proc. pmid:11120281
Bierer BE et al. FK 506 and rapamycin: molecular probes of T-lymphocyte activation. 1991 Transplant. Proc. pmid:1721296
Lipson DA et al. Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. 1998 Transplant. Proc. pmid:9636612
Braun F et al. An ex vivo model to study the intestinal biotransformation of immunosuppressives. 2000 Transplant. Proc. pmid:11120282
Wiebe K et al. FK506 rescue therapy in lung transplantation. 1998 Transplant. Proc. pmid:9636613
Woodle ES et al. Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: the Chicago experience. 1999 Transplant. Proc. pmid:10576053
Vanrenterghem Y Vascular rejection with tacrolimus and potential long-term graft outcome. 1999 Transplant. Proc. pmid:10576054
Sathyan S et al. A case of recurrent immunotactoid glomerulopathy in an allograft treated with rituximab. 2009 Transplant. Proc. pmid:19917422
Iaria G et al. Prospective study of switch from cyclosporine to tacrolimus for fibroadenomas of the breast in kidney transplantation. 2010 Transplant. Proc. pmid:20534252
Woodle ES A prospective, randomized, multicenter, double-blind study of early corticosteroid cessation versus long-term maintenance of corticosteroid therapy with tacrolimus and mycophenolate mofetil in primary renal transplant recipients: one year report. 2005 Transplant. Proc. pmid:15848538
López-Montenegro Soria MA et al. Genetic polymorphisms and individualized tacrolimus dosing. 2010 Transplant. Proc. pmid:20970601
Lodewijk L et al. Effect of liver regeneration on the pharmacokinetics of immunosuppressive drugs. 2009 Jan-Feb Transplant. Proc. pmid:19249561
Nowacka-Cieciura E et al. Late conversion to everolimus complicated with necrotizing glomerulonephritis in a renal allograft recipient: case report. 2009 Jan-Feb Transplant. Proc. pmid:19249576
Takada Y et al. Energy metabolism of hepatic allografts subjected to prolonged warm ischemia and pharmacologic modulation with FK506 and platelet activating factor antagonist. 1998 Transplant. Proc. pmid:9838621
Tiebosch A et al. Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. 1990 Transplant. Proc. pmid:1697115
Dammeijer PF et al. Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. 1990 Transplant. Proc. pmid:1697116
Ebbs A et al. Tacrolimus treats ongoing allograft rejection by inhibiting interleukin-10 mediated functional cytotoxic cell infiltration. 2002 Transplant. Proc. pmid:12176404
Okamoto M et al. Detection of allograft rejection in rat small bowel transplantation by analysing the in situ distribution of S-phase lymphocytes. 1994 Transplant. Proc. pmid:7518145
Hisanaga M et al. Successful combination therapy with FK 506 and 15-deoxyspergualin in pancreatic islet xenografting. 1992 Transplant. Proc. pmid:1376513
Barkholt LM et al. New criteria for diagnosing cytomegalovirus hepatitis in liver transplant patients. 1995 Transplant. Proc. pmid:7533375
Didlake R and Grogan J Effect of FK 506 on rat leukocyte chemotaxis. 1991 Transplant. Proc. pmid:1721327
Akioka K et al. Abdominal pain is a critical complication of mycophenolate mofetil in renal transplant recipients. 2003 Transplant. Proc. pmid:12591411
Hohage H et al. Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function. 2005 Transplant. Proc. pmid:15919453
Borda B et al. Early histopathological changes in new-onset diabetes after kidney transplantation. Transplant. Proc. pmid:25131129
Porubsky M et al. Excellent outcomes can be achieved in young pancreas transplant alone recipients by addition of sirolimus to maintenance immunosuppression regimen. Transplant. Proc. pmid:25131074
Sakamoto K et al. Sodium-losing nephropathy and distal tubular damage of transplant kidneys with FK506 administration. 1995 Transplant. Proc. pmid:7533434
Ochiai T et al. Phase III study of FK 506 in kidney transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533435
Escartín A et al. Analysis of pig-MAP after small bowel transplantation in pigs. 1998 Transplant. Proc. pmid:9865377
Armitage JM et al. The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. 1991 Transplant. Proc. pmid:1721358
Reis A et al. Mycophenolate mofetil and FK506: two novel immunosuppressants in murine corneal transplantation. 1998 Transplant. Proc. pmid:9865380
Nalesnik MA et al. Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. 1991 Transplant. Proc. pmid:1703335
Armitage JM et al. The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. 1991 Transplant. Proc. pmid:1721359
Armitage JM et al. A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. 1991 Transplant. Proc. pmid:1703336
Emiroglu R et al. Tacrolimus-related neurologic and renal complications in liver transplantation: A single-center experience. 2006 Transplant. Proc. pmid:16549190
Prates LC et al. Pain syndrome induced by calcineurin inhibitor and resolved by conversion to sirolimus in a child after kidney transplantation: a case report. 2012 Transplant. Proc. pmid:23026634
Martin Garcia D et al. Tacrolimus-Basiliximab versus Cyclosporine-Basiliximab in renal transplantation "de novo": acute rejection and complications. 2003 Transplant. Proc. pmid:12962761
Naraghi RM et al. Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection. 1997 Feb-Mar Transplant. Proc. pmid:9123013
Nishi K et al. The expression of intestinal CYP3A4 in the piglet model. 2004 Transplant. Proc. pmid:15050159
Velio P et al. Rejection and survival after total orthotopic liver-small bowel allotransplantation in pigs immunosuppressed with FK 506. 1996 Transplant. Proc. pmid:8907936
Sonnenday CJ et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. 2002 Transplant. Proc. pmid:12176507
Di Benedetto F et al. University of Modena experience in HIV-positive patients undergoing liver transplantation. 2011 Transplant. Proc. pmid:21620066
Rastellini C et al. Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. 1999 Feb-Mar Transplant. Proc. pmid:10083278
Morimoto T et al. Blood levels of FK506 after intramuscular and intravenous administration in dogs. 1989 Transplant. Proc. pmid:2468207
Doi R et al. Mechanisms by which FK 506 affects exocrine pancreas in rats. 1991 Transplant. Proc. pmid:1721392
Jambaljav L et al. Kidney transplantation achievements in Mongolia. 2010 Transplant. Proc. pmid:20430173
Millis JM et al. Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy. 1997 Feb-Mar Transplant. Proc. pmid:9123421
Corry RJ et al. Pancreas transplantation with enteric drainage under tacrolimus induction therapy. 1997 Feb-Mar Transplant. Proc. pmid:9123457
Uchida K et al. Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. 2002 Transplant. Proc. pmid:12176556
Klupp J et al. New approach in drug development: whole blood pharmacodynamic assays reflect biological activities of tacrolimus. 2001 Transplant. Proc. pmid:11377491
Mollison KW et al. Discovery of FK 506 analogues that are nontoxic to mouse pancreatic beta cells in vitro but show diabetogenic potential when administered to the rat. 1996 Transplant. Proc. pmid:8962236
Pozzetto U et al. Effects of immunosuppressive regimens on plasma levels of transforming growth factor-beta 1 in renal transplant recipients. 2002 Transplant. Proc. pmid:12176558
McGrath JS and Shehata M The effect of differing immunosuppressive regimes on the functional and morphologic changes in a rat renal allograft model of chronic rejection. 2001 Transplant. Proc. pmid:11377499
Yokoyama I et al. Decreased Fas antigen expression of cultured hepatocytes with FK 506. 1996 Transplant. Proc. pmid:8962237
Koefoed-Nielsen PB and Jørgensen KA Alterations in calcineurin phosphatase activity in tacrolimus-treated renal transplant patients. 2002 Transplant. Proc. pmid:12176559
Mao PC et al. Trends in the use of immunosuppressive agents by outpatients after renal transplantation at a medical center in southern Taiwan. 2012 Transplant. Proc. pmid:22310611
Calconi G and Vianello A One-year follow-up of a large European trial comparing dual versus triple tacrolimus-based immunosuppressive regimens following renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267173
Yoshimi F et al. Canine total orthotopic small bowel transplantation under FK 506. 1991 Transplant. Proc. pmid:1721422
Kawauchi M et al. Which are the target vessels of xeno- and allo-lung rejection?--a primate single lung transplantation study. 1996 Transplant. Proc. pmid:8658719
Dresske B et al. Synergistic impact of "WOFIE" on the immunosuppressive potency of FK 506 in a heterotopic heart transplantation model in the rat. 1999 Transplant. Proc. pmid:10331001
Nayeri A et al. Acute Calcineurin Inhibitor Nephrotoxicity Secondary to Turmeric Intake: A Case Report. Transplant. Proc. pmid:28104136
Sicilia-Castro D et al. Reconstruction of a severe facial defect by allotransplantation in neurofibromatosis type 1: a case report. 2011 Transplant. Proc. pmid:21911174
Collier DS et al. FK-506 in experimental renal allografts. 1987 Transplant. Proc. pmid:2445063
Kanatani T et al. Donor leukocytes combine with immunosuppressive drug therapy to prolong limb allograft survival. 2005 Transplant. Proc. pmid:15964421
Lang M et al. Combined liver-kidney transplantation: long-term follow-up in 18 patients. 1998 Transplant. Proc. pmid:9723313
Gnatta D et al. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study. 2010 Transplant. Proc. pmid:20304169
Trotter JF Sirolimus in liver transplantation. 2003 Transplant. Proc. pmid:12742496
Ventura E et al. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring. 2009 Transplant. Proc. pmid:19328963
Ojogho ON et al. Mycophenolate mofetil without antibody induction in pediatric renal transplantation. 2002 Transplant. Proc. pmid:12176641
van der Laan LJ et al. Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus. 2010 Transplant. Proc. pmid:21168740
Gruttadauria S et al. A safe immunosuppressive protocol in adult-to-adult living related liver transplantation. 2006 Transplant. Proc. pmid:16757278
Nanmoku K et al. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus. 2018 Transplant. Proc. pmid:29631750
Markus BH et al. Daclizumab induction therapy in combination with tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11267354
Takahara S et al. Clinical evaluation of trough levels and area under the curve in cyclosporine- and FK 506-treated kidney transplant recipients. 1994 Transplant. Proc. pmid:7524219
Llull R et al. Multilineage amplification of graft-vs-host disease-resistant chimerism following rat vascularized bone marrow allotransplantation. 1995 Transplant. Proc. pmid:7544504
Langrehr JM et al. IL-2 receptor antibody induction increases the risk for chronic rejection after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267360
Heitman J et al. Antifungal effects of cyclosporine and FK 506 are mediated via immunophilin-dependent calcineurin inhibition. 1994 Transplant. Proc. pmid:7524220
Heffron TG et al. Single-dose induction with daclizumab immediately after liver transplantation in pediatric patients. 2001 Feb-Mar Transplant. Proc. pmid:11267368
Sainsbury TS et al. Differential effects of FK 506 and cyclosporine on hair regrowth in the DEBR model of alopecia areata. 1991 Transplant. Proc. pmid:1721453
González MG et al. Comparison of post-liver transplantation electrocardiographic alterations between cyclosporine- and tacrolimus-treated patients. 1999 Transplant. Proc. pmid:10500652
Chang HK et al. Ten-Year Experience With Bowel Transplantation at Seoul St. Mary's Hospital. 2016 Transplant. Proc. pmid:27109981
Fujino Y et al. FK 506 treatment of experimental autoimmune uveoretinitis in primates. 1991 Transplant. Proc. pmid:1721454
González-Pinto I et al. Usefulness of the switch to tacrolimus in liver transplantation. 1999 Transplant. Proc. pmid:10500653
Wang M et al. Acute influence of FK506 on T-lymphocyte populations of peripheral blood and spleen in rats. 2007 Jan-Feb Transplant. Proc. pmid:17275526
Carroll PB et al. Effect of the immunosuppressant FK 506 on insulin release from adult rat islets of Langerhans. 1991 Transplant. Proc. pmid:1703688
Eghtesad B et al. Use of tacrolimus as the primary immunosuppression after renal transplant in Native Americans and Hispanics. 1998 Transplant. Proc. pmid:9636500
Pichlmayr R et al. Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study. 1997 Transplant. Proc. pmid:9270825